138 related articles for article (PubMed ID: 34825744)
1. Intralesional biologics for inflammatory dermatoses: A systematic review.
Seivright JR; Villa NM; De DR; Hsiao JL; Shi VY
Dermatol Ther; 2022 Feb; 35(2):e15234. PubMed ID: 34825744
[TBL] [Abstract][Full Text] [Related]
2. Generalized Pyoderma Gangrenosum Associated with Ulcerative Colitis: Successful Treatment with Infliximab and Azathioprine.
Chatzinasiou F; Polymeros D; Panagiotou M; Theodoropoulos K; Rigopoulos D
Acta Dermatovenerol Croat; 2016 Apr; 24(1):83-5. PubMed ID: 27149138
[TBL] [Abstract][Full Text] [Related]
3. Pyoderma gangrenosum and tumour necrosis factor alpha inhibitors: A semi-systematic review.
Ben Abdallah H; Fogh K; Bech R
Int Wound J; 2019 Apr; 16(2):511-521. PubMed ID: 30604927
[TBL] [Abstract][Full Text] [Related]
4. A systematic review on biological therapies in juvenile idiopathic inflammatory myopathies: an evidence gap in precision medicine.
Marrani E; Abu-Rumeileh S; Mastrolia MV; Maccora I; Pagnini I; Simonini G
Clin Exp Rheumatol; 2022 Feb; 40(2):457-470. PubMed ID: 34905479
[TBL] [Abstract][Full Text] [Related]
5. Inflammatory arthritis-associated pyoderma gangrenosum: a systematic review.
Sawka E; Zhou A; Latour E; Friedman M; Ortega-Loayza AG
Clin Rheumatol; 2021 Oct; 40(10):3963-3969. PubMed ID: 34002351
[TBL] [Abstract][Full Text] [Related]
6. Biologic Therapy in the Treatment of Cutaneous Sarcoidosis: A Literature Review.
Dai C; Shih S; Ansari A; Kwak Y; Sami N
Am J Clin Dermatol; 2019 Jun; 20(3):409-422. PubMed ID: 30895525
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of biologic therapies in psoriasis vulgaris.
Mala R; Fida M; Jorgaqi E; Vasili E
Dermatol Ther; 2019 Jul; 32(4):e12936. PubMed ID: 30983095
[TBL] [Abstract][Full Text] [Related]
8. Biologics and immunoglobulins in the treatment of pyoderma gangrenosum - analysis of 52 patients.
Herberger K; Dissemond J; Brüggestrat S; Sorbe C; Augustin M
J Dtsch Dermatol Ges; 2019 Jan; 17(1):32-41. PubMed ID: 30592563
[TBL] [Abstract][Full Text] [Related]
9. Treatment options for pyoderma gangrenosum.
Quist SR; Kraas L
J Dtsch Dermatol Ges; 2017 Jan; 15(1):34-40. PubMed ID: 28140549
[TBL] [Abstract][Full Text] [Related]
10. Etanercept, infliximab and adalimumab for the treatment of psoriatic arthritis: a systematic review and economic evaluation.
Rodgers M; Epstein D; Bojke L; Yang H; Craig D; Fonseca T; Myers L; Bruce I; Chalmers R; Bujkiewicz S; Lai M; Cooper N; Abrams K; Spiegelhalter D; Sutton A; Sculpher M; Woolacott N
Health Technol Assess; 2011 Feb; 15(10):i-xxi, 1-329. PubMed ID: 21333232
[TBL] [Abstract][Full Text] [Related]
11. Pyoderma gangrenosum: clinical characteristics, associated diseases, and responses to treatment in a retrospective cohort study of 31 patients.
Vacas AS; Torre AC; Bollea-Garlatti ML; Warley F; Galimberti RL
Int J Dermatol; 2017 Apr; 56(4):386-391. PubMed ID: 28295267
[TBL] [Abstract][Full Text] [Related]
12. Cost of biologics per treated patient across immune-mediated inflammatory disease indications in a pharmacy benefit management setting: a retrospective cohort study.
Wu N; Lee YC; Shah N; Harrison DJ
Clin Ther; 2014 Aug; 36(8):1231-41, 1241.e1-3. PubMed ID: 25062652
[TBL] [Abstract][Full Text] [Related]
13. [Treatment of plaque psoriasis with biologics. A meta-analysis of randomized controlled trials].
Zhang Z; Schmitt J; Wozel G; Kirch W
Med Klin (Munich); 2009 Feb; 104(2):125-36. PubMed ID: 19242664
[TBL] [Abstract][Full Text] [Related]
14. [The role of biologic therapy in the treatment of extraintestinal manifestations and complications of inflammatory bowel disease].
Kujundzić M
Acta Med Croatica; 2013 Apr; 67(2):195-201. PubMed ID: 24471303
[TBL] [Abstract][Full Text] [Related]
15. Use of biologics for treatment of autoimmune inner ear disease.
Balouch B; Meehan R; Suresh A; Zaheer HA; Jabir AR; Qatanani AM; Suresh V; Kaleem SZ; McKinnon BJ
Am J Otolaryngol; 2022; 43(5):103576. PubMed ID: 35963108
[TBL] [Abstract][Full Text] [Related]
16. The Role of Biologic Therapies in Dermatology.
Fathi R; Armstrong AW
Med Clin North Am; 2015 Nov; 99(6):1183-94. PubMed ID: 26476247
[TBL] [Abstract][Full Text] [Related]
17. Experience With Anti-TNF-α Biologic Agents in Succession in Patients With Crohn's Disease: A Retrospective Analysis of a Single Center.
Ferges W; Rampertab SD; Shafqet M; Salimi Q; You G; Yousefzadeh E; Cheng JQ; Das KM
J Clin Gastroenterol; 2016 Apr; 50(4):326-30. PubMed ID: 25984976
[TBL] [Abstract][Full Text] [Related]
18. [Biologics in skin diseases other than psoriasis].
Gniadecki R; Skov L
Ugeskr Laeger; 2008 Jun; 170(24):2126-8. PubMed ID: 18565293
[TBL] [Abstract][Full Text] [Related]
19. Tumor necrosis factor-α inhibitors for the treatment of pyoderma gangrenosum not associated with inflammatory bowel diseases: A multicenter retrospective study.
Rousset L; de Masson A; Begon E; Villani A; Battistella M; Rybojad M; Jachiet M; Bagot M; Bouaziz JD; Lepelletier C
J Am Acad Dermatol; 2019 Apr; 80(4):1141-1143. PubMed ID: 30342166
[No Abstract] [Full Text] [Related]
20. Treatment patterns and annual biologic costs in US veterans with rheumatic conditions or psoriasis.
Sauer BC; Teng CC; He T; Leng J; Lu CC; Walsh JA; Shah N; Harrison DJ; Tang DH; Cannon GW
J Med Econ; 2016; 19(1):34-43. PubMed ID: 26337538
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
